Heidi J. Einolf

3.7k citations

39 papers · 1.6k indexed · h-index 25

Pharmacology top 0.2%
Molecular Biology
Oncology top 5%
Computational Theory and Mathematics top 5%
Pediatrics, Perinatology and Child Health top 10%

Co-authors: F. Peter Guengerich Helen Gu Nathalie Schnetz‐Boutaud Michael Sinz Handan He James B. Mangold Lai Wang R. Scott Obach
Topics: Pharmacogenetics and Drug Metabolism (24 papers)Drug Transport and Resistance Mechanisms (12 papers)Statistical Methods in Clinical Trials (8 papers)
Cited by: Pharmacology Oncology Computational Theory and Mathematics
Journals: Journal of Biological Chemistry Biochemistry Journal of Pharmaceutical Sciences
Partner nations: United States Switzerland India

In The Last Decade

Heidi J. Einolf

37 papers receiving 1.5k citations

Peers

Countries citing papers authored by Heidi J. Einolf

Since Specialization

Citations

This map shows the geographic impact of Heidi J. Einolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi J. Einolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi J. Einolf more than expected).

Fields of papers citing papers by Heidi J. Einolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi J. Einolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi J. Einolf. The network helps show where Heidi J. Einolf may publish in the future.

Co-authorship network of co-authors of Heidi J. Einolf

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi J. Einolf. A scholar is included among the top collaborators of Heidi J. Einolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi J. Einolf. Heidi J. Einolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib 2025 ·Pharmaceutics ·(unknown),Felix Huth,Matthias Hoch,Heidi J. Einolf	0
2	Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials 2025 ·Drug Metabolism and Disposition ·(unknown),Romain Séchaud,Imad Hanna,Ryan M. Pelis,Heidi J. Einolf	1
3	Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study 2025 ·Tropical Medicine and Health ·(unknown),Nada Abla,Vinay Kumar Venishetty,Birgit Schoeberl,(unknown),Heidi J. Einolf	0
4	Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment 2020 ·Drug Metabolism and Disposition ·Simon Wong,Diane Ramsden,Shannon Dallas,(unknown),Heidi J. Einolf,Jairam Palamanda,Liangfu Chen,Theunis C. Goosen,(unknown),George Zhang,Donald Tweedie,Niresh Hariparsad,Barry Jones,Phillip D. Yates	17
5	Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches 2017 ·Drug Metabolism and Disposition ·(unknown),Helen Gu,(unknown),Heidi J. Einolf	25
6	Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model 2017 ·Journal of Pharmaceutical Sciences ·(unknown),(unknown),Heidi J. Einolf,Surya Ayalasomayajula,Tsu‐Han Lin,Imad Hanna,Tycho Heimbach,C. Breen,Venkateswar Jarugula,Handan He	18
7	Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control 2017 ·Drug Metabolism and Disposition ·Niresh Hariparsad,Diane Ramsden,Jairam Palamanda,(unknown),Odette A. Fahmi,Jane R. Kenny,Heidi J. Einolf,Michael A. Mohutsky,(unknown),(unknown),Liangfu Chen,Michael Sinz,Barry Jones,Robert L. Walsky,Shannon Dallas,Suresh K. Balani,George Zhang,David B. Buckley,Donald Tweedie	33
8	Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin 2017 ·Drug Metabolism and Disposition ·Helen Gu,Catherine Dutreix,Sam Rebello,Taoufik Ouatas,Lai Wang,(unknown),Heidi J. Einolf,Handan He	25
9	A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug–Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients 2017 ·Drug Metabolism and Disposition ·Heidi J. Einolf,(unknown),(unknown),Lai Wang,Sam Rebello	27
10	Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective 2016 ·Drug Metabolism and Disposition ·Odette A. Fahmi,Mohamad Shebley,Jairam Palamanda,Michael Sinz,Diane Ramsden,Heidi J. Einolf,(unknown),Hongwu Wang	38
11	Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans 2016 ·Drug Metabolism and Disposition ·S.-E. W. Huskey,Chunqi Zhu,Mei‐Jin Lin,Ry R. Forseth,Gu He,Oliver Simon,(unknown),Matthias Kittelmann,(unknown),(unknown),Huixia Li,(unknown),Heidi J. Einolf,Jie Zhang,(unknown),Handan He,(unknown)	8
12	Evaluation of Calibration Curve–Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes 2014 ·Drug Metabolism and Disposition ·George Zhang,(unknown),(unknown),R. J. H. Clark,(unknown),(unknown),Deqing Xiao,(unknown),Heidi J. Einolf,David M. Stresser	26
13	Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data 2013 ·Clinical Pharmacology & Therapeutics ·Heidi J. Einolf,(unknown),Odette A. Fahmi,Christopher R. Gibson,R. Scott Obach,Mohamad Shebley,(unknown),Michael Sinz,Jashvant D. Unadkat,L Zhang,Ping Zhao	73
14	Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects 2013 ·The Journal of Clinical Pharmacology ·Shyeilla V. Dhuria,Heidi J. Einolf,James B. Mangold,(unknown),Helen Gu,Lai Wang,Scott B. Cameron	17
15	Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development 2011 ·Current Topics in Medicinal Chemistry ·David O. Nettleton,Heidi J. Einolf	37
16	Cytochrome P450 1A2 Detoxicates Aristolochic Acid in the Mouse 2010 ·Drug Metabolism and Disposition ·Thomas A. Rosenquist,Heidi J. Einolf,Kathleen G. Dickman,Lai Wang,Amanda Smith,Arthur P. Grollman	51
17	The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America 2009 ·Drug Metabolism and Disposition ·Scott Grimm,Heidi J. Einolf,(unknown),Kan He,Heng‐Keang Lim,(unknown),Chuang Lu,Amin A. Nomeir,Eleanore Seibert,Konstantine W. Skordos,George Tonn,Robert Van Horn,Regina W. Wang,Y. Nancy Wong,Tian J. Yang,R. Scott Obach	224
18	Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans 2008 ·Drug Metabolism and Disposition ·Handan He,(unknown),Hequn Yin,Harold T. Smith,Yannick Batard,Lai Wang,Heidi J. Einolf,Helen Gu,James B. Mangold,Volker Fischer,Dan Howard	119
19	Efflux Transporters and their Clinical Relevance 2005 ·Mini-Reviews in Medicinal Chemistry ·Volker Fischer,Heidi J. Einolf,Dalia Cohen	24
20	Benzo(c)phenanthrene is activated to DNA-binding diol epoxides in the human mammary carcinoma cell line MCF-7 but only limited activation occurs in mouse skin 1996 ·Carcinogenesis ·Heidi J. Einolf,Shantu Amin,Haruhiko Yagi,Donald M. Jerina,William M. Baird	24

About Heidi J. Einolf

Heidi J. Einolf is a scholar working on Pharmacology, Statistics and Probability and Oncology, having authored 39 papers that have together received 1.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (24 papers), Drug Transport and Resistance Mechanisms (12 papers) and Statistical Methods in Clinical Trials (8 papers). The work is most often cited by research in Pharmacology (776 citations), Oncology (499 citations) and Computational Theory and Mathematics (176 citations). Heidi J. Einolf has collaborated with scholars based in United States, Switzerland and India. Frequent co-authors include F. Peter Guengerich, Helen Gu, Nathalie Schnetz‐Boutaud, Michael Sinz, Handan He, James B. Mangold, Lai Wang, Lai Wang, R. Scott Obach and David O. Nettleton. Their work appears in journals such as Journal of Biological Chemistry, Biochemistry and Journal of Pharmaceutical Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact